Vapotherm Blog
CAUTION: US Federal law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at https://vapotherm.com/resources/support/precision-flow-reference/. For spontaneously breathing patients. High Velocity Therapy (HVT) does not provide total ventilatory requirements of the patient. It is not a ventilator. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case, including escalation of care depending on patient condition.
Vapotherm provides high velocity nasal insufflation (HVNI) with simultaneous oxygen delivery to augment breathing of spontaneously breathing patients suffering from respiratory distress and/or hypoxemia in the hospital setting. It is not intended to provide total ventilatory requirements of the patient and not for use during field transport.
The information provided in this section is for educational purposes only. This information is not intended to support the safety or effectiveness of Vapotherm products, or diagnose, treat, cure, or prevent any disease. It is not a substitute for consultation with your healthcare provider and should not be construed as medical advice.
Vapotherm® Announces FDA 510(k) Clearance for the All Patient Circuit™, Enabling High Velocity Therapy for Neonatal to Adult Patients
EXETER, N.H – Vapotherm, Inc., a developer and manufacturer of advanced respiratory technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its All Patient Circuit (APC™) which now includes therapy settings for neonatal and infant patients. The cleared APC enables the HVT 2.0 high velocity therapy system to deliver therapy across a 2–45 L/min flow range using a single disposable patient circuit.
Vapotherm and Flight Medical Announce Partnership to Bring the VentO2ux™ Ventilator to US Hospitals
EXETER, N.H., December 8, 2025 – Vapotherm, Inc., a leader in advanced respiratory support technologies, today announced a strategic partnership with Flight Medical Innovations Ltd. to bring the newly cleared VentO2ux™ ventilator to customers in the United States. The collaboration expands Vapotherm’s portfolio beyond high velocity therapy devices to a broader platform of respiratory support solutions spanning the continuum of care.
Vapotherm HVT® 2.0 Earns DoD Authority to Operate Certification, Advancing Secure Respiratory Support for Military and VA Hospitals
Vapotherm, Inc., a global leader in mask-free noninvasive respiratory support, announced its HVT® 2.0 system has received Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF).
New Study Confirms Vapotherm’s Unicorn™ Cannula Provides Comparable Efficacy at Lower Flow Rates
Vapotherm, Inc., the global leader in mask-free noninvasive respiratory support, is proud to announce the publication of a new clinical study, Effect of Single-Prong Cannula Design with High Velocity Therapy: Comparable Efficacy at Lower Gas Flow Rates, in Critical Care Explorations. The study demonstrates that the ProSoft® Unicorn™ Cannula, a single-prong high velocity therapy cannula, provides comparable relief of dyspnea at a significantly lower flow rates compared to traditional dual-prong cannulas.
Vapotherm Introduces the Unicorn™ Cannula: A Next Generation, Single-Prong Cannula Designed for Optimal CO2 Clearance
Vapotherm, Inc., a leader in mask-free noninvasive respiratory support, introduces the Unicorn Cannula, an innovative single-prong addition to the ProSoft® series. Designed to enhance CO₂ clearance and patient comfort, the Unicorn Cannula retains the proven small-bore technology while enhancing therapy effectiveness.
HYPERACT Trial Published: A Paradigm Shift in Respiratory Care
The publication of “High-Velocity Nasal Insufflation vs Non-Invasive Positive Pressure Ventilation for Moderate Acute Exacerbation of COPD in the ED”
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company’s commitment to improving the lives of hypercapnic patients in the home. “Our mission is to improve quality of life and reduce hospital readmissions for patients who struggle with respiratory disease. Access365 will provide optimal treatment at home, especially for COPD patients, by combining the known benefits of nocturnal NIV with the comfort of high velocity therapy for daytime use.”
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and future Home system
Letting Children be Children
While the advantages of early mobility in critical care are widely acknowledged, its profound impact on patient mental well-being is equally significant. Hear from this Paediatric team at Freeman Hospital, Newcastle, UK, as they share their experience on how much Vapotherm’s mobility solution positively impacts their patients and their families.
Five Benefits Vapotherm HVT 2.0 Can Offer Your Small (Sometimes Rural) Hospital
Does your hospital struggle finding a safe, effective, easy to use respiratory support option for stabilizing patients in respiratory distress? Vapotherm’s HVT 2.0 advanced respiratory support platform provides fast and effective support for your patients in respiratory distress. HVT 2.0 prioritizes safety, comfort, and convenience for both patients and clinical staff. Learn how your facility can realize these benefits by testing the performance of HVT 2.0 and assess its suitability for various patient cases with no upfront commitment through Vapotherm’s Trial Program!